natgillin/translations-raw huggingface dataset:
Children and adolescents (8 to 17 years of age) Tigecycline is only to be used to treat patients aged 8 years and older after consultation with a physician with appropriate experience in the management of infectious diseases.
Tigeciklin se smije upotrebljavati za liječenje bolesnika u dobi od 8 godina i starijih samo nakon savjetovanja s liječnikom koji ima odgovarajuće iskustvo u liječenju infektivnih bolesti.
The reconstituted solution should be yellow to orange in colour; if not, the solution should be discarded.
Pripremljena otopina trebala bi biti žute do narančaste boje; ukoliko to nije slučaj, otopinu treba odbaciti.
In in vitro studies, no antagonism has been observed between tigecycline and other commonly used antibiotic classes.
U in vitro ispitivanjima nije opažen antagonizam između tigeciklina i ostalih često primjenjivanih skupina antibiotika.
Do not take any diarrhoea medicine without first checking with your doctor.
Nemojte uzimati lijekove protiv proljeva prije nego što se posavjetujete s Vašim liječnikom.
Results of animal studies indicate that tigecycline crosses the placenta and is found in foetal tissues.
Rezultati ispitivanja na životinjama upućuju na to da tigeciklin prolazi kroz posteljicu i može se naći u fetalnim tkivima.
The following active substances should not be administered simultaneously through the same Y-site as tigecycline: Amphotericin B, amphotericin B lipid complex, diazepam, esomeprazole, omeprazole and intravenous solutions that could result in an increase of pH above 7.
Slijedeće djelatne tvari ne smiju se primjenjivati kroz istu infuzijsku Y-liniju istovremeno s tigeciklinom: amfotericin B, amfotericin B lipidni kompleks, diazepam, esomeprazol, omeprazol i intravenske otopine koje mogu povisiti pH iznad 7.
Limited experience is also available in treating patients with concurrent bacteraemia (3.4 %).
Također postoji samo ograničeno iskustvo u liječenju bolesnika s istovremenom bakterijemijom (3,4%).
Patients with severe underlying disease, such as those that were immunocompromised, patients with decubitus ulcer infections, or patients that had infections requiring longer than 14 days of treatment (for example, necrotizing fasciitis), were not enrolled.
U ispitivanja nisu bili uključeni bolesnici s teškom osnovnom bolešću, poput onih koji su imunokompromitirani, zatim bolesnici s infekcijama dekubitalnog ulkusa ili bolesnici s infekcijom koja je zahtijevala više od 14 dana liječenja (primjerice, nekrotizirajući fasciitis).
Based on an in vitro study tigecycline is a P-gp substrate.
Na temelju in vitro studija tigeciklin je P-gp supstrat.
A dosing regimen of 1.2 mg/kg of tigecycline every 12 hours (to a maximum dose of 50 mg every 12 hours) for children aged 8 to <12 years and of 50 mg every 12 hours for adolescents aged 12 to <18 years would likely result in exposures comparable to those observed in adults treated with the approved dosing regimen.
Režim doziranja od 1,2 mg/kg tigeciklina svakih 12 sati (do maksimalne doze od 50 mg svakih 12 sati) za djecu u dobi od 8 do <12 i od 50 mg svakih 12 sati za adolescente u dobi od 12 do <18 najvjerojatnije će rezultirati izloženostima usporedivim s uočenima u odraslih liječenih odobrenim režimom doza.
Glycylcycline class antibiotics are structurally similar to tetracycline class antibiotics.
Glicilciklinski razred antibiotika je strukturno sličan tetraciklinskom razredu antibiotika.
Tigecycline should be preferably administered over a 60-minute length of infusion in paediatric patients.
Tigeciklin treba po mogućnosti primjenjivati u infuziji trajanja 60 minuta u pedijatrijskih bolesnika.
However, since tigecycline may prolong both prothrombin time (PT) and activated partial thromboplastin time (aPTT), the relevant coagulation tests should be closely monitored when tigecycline is co-administered with anticoagulants (see section 4.4).
Međutim, budući da tigeciklin može produžiti kako protrombinsko vrijeme (PV), tako i aktivirano parcijalno tromboplastinsko vrijeme (APTV), potrebna je česta kontrola relevantnih koagulacijskih testova u slučaju istovremene primjene tigeciklina i antikoagulansa (vidjeti dio 4.4).
What Tygacil looks like and contents of the pack Tygacil is supplied as a powder for solution for infusion in a vial and looks like an orange powder or cake before it is diluted.
Tygacil je dostupan kao prašak za otopinu za infuziju u bočici i prije razrjeđivanja izgleda kao narančasti prašak ili kolačić.
When administered through a Y-site, compatibility of tigecycline diluted in sodium chloride 0.9 % for injection is demonstrated with the following medicinal products or diluents: amikacin, dobutamine, dopamine HCl, gentamicin, haloperidol, Lactated Ringer's, lidocaine HCl, metoclopramide, morphine, norepinephrine, piperacillin/tazobactam (EDTA formulation), potassium chloride, propofol, ranitidine HCl, theophylline, and tobramycin.
U slučaju primjene kroz Y-liniju, dokazana je kompatibilnost tigeciklina razrijeđenog u 0,9%-tnoj otopini natrijevog klorida sa slijedećim lijekovima ili otapalima: amikacin, dobutamin, dopaminklorid, gentamicin, haloperidol, Ringerova otopina s laktatom, lidokainklorid, metoklopramid, morfin, norepinefrin, piperacilin/tazobaktam (EDTA formulacija), kalijev klorid, propofol, ranitidinklorid, teofilin i tobramicin.
Therefore, clearance of tigecycline is not expected to be affected by active substances that inhibit or induce the activity of the CYP450 isoforms.
Stoga se ne očekuje značajniji utjecaj djelatnih tvari koje inhibiraju ili induciraju aktivnost izoenzima CYP450 na klirens tigeciklina.
Digoxin did not affect the pharmacokinetic profile of tigecycline.
Digoksin nije utjecao na farmakokinetički profil tigeciklina.
In clinical pharmacology studies using the therapeutic dosage regimen of 100 mg followed by 50 mg q12h, serum tigecycline steady-state Cmax was 866±233 ng/ml for 30-minute infusions and 634±97 ng/ml for 60-minute infusions.
U kliničkim farmakološkim ispitivanjima u kojima je primjenjivana terapijska shema doziranja od 100 mg, nakon čega slijedi 50 mg svakih 12 sati, Cmax serumskog tigeciklina u stanju dinamičke ravnoteže iznosila je 866±233 ng/ml za 30-minutnu infuziju, odnosno 634±97 ng/ml za 60-minutne infuzije.
The adverse reaction profile of tigecycline in these 58 subjects was generally consistent with that in adults, with the exception of nausea (48.3 %), vomiting (46.6 %) and elevated lipase in serum (6.9 %) which were seen at greater frequencies in children than in adults.
Profil nuspojava tigeciklina u tih 58 ispitanika općenito je bio dosljedna profilu odraslih, uz mučninu (48,3 %), povraćanje (46,6 %) i povećane lipaze u serumu (6,9 %) kao iznimke koje su učestalije primijećene u djece nego u odraslih.
C-tigecycline, radioactivity was well distributed to most tissues, with the highest overall exposure observed in bone marrow, salivary glands, thyroid gland, spleen, and kidney.
C-tigeciklina, radioaktivnost se dobro distribuirala u većinu tkiva, pri čemu je najveća ukupna ekspozicija opažena u koštanoj srži, žlijezdama slinovnicama, štitnjači, slezeni i bubrezima.
Single dose
Jedna doza
Decreased susceptibility in both groups has been attributed to the overexpression of the non-specific AcrAB multi-drug efflux pump.
Smanjena osjetljivost u obje se skupine pripisuje pretjeranoj ekspresiji nespecifične AcrAB efluks pumpe za više lijekova.
Do not use this medicine after the expiry date which is stated on the vial.
Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na bočici.
The Tygacil solution should be yellow to orange in colour after dissolving; if it is not, the solution should be discarded.
Otopina Tygacila nakon otapanja treba biti žute do narančaste boje; ukoliko to nije slučaj, otopinu treba baciti.
How to store Tygacil
Kako primjenjivati Tygacil
Marketing Authorisation Holder Pfizer Europe MA EEIG Boulevard de la Plaine 17 1050 Bruxelles
Nositelj odobrenja Pfizer Europe MA EEIG Boulevard de la Plaine 17 1050 Bruxelles Belgija
• Complicated skin and soft tissue infections (cSSTI), excluding diabetic foot infections (see section 4.4);
• Komplicirane infekcije kože i mekih tkiva, isključujući infekcije dijabetičkog stopala (vidjeti dio 4.4);
There are no or limited amount of data from the use of tigecycline in pregnant women.
Nema podataka ili su podaci o primjeni tigeciklina u trudnica ograničeni.
Animal and human pharmacokinetic studies have demonstrated that tigecycline readily distributes to tissues.
Farmakokinetička ispitivanja na životinjama i ljudima pokazale su da se tigeciklin brzo distribuira u tkiva.
Warfarin did not affect the pharmacokinetic profile of tigecycline.
Varfarin nije utjecao na farmakokinetički profil tigeciklina.
• Abdominal pain, dyspepsia (stomach ache and indigestion), anorexia (loss of appetite)
• Bol u trbuhu, dispepsija (bol u želucu i probavne smetnje), anoreksija (gubitak apetita)
A limited number of patients were enrolled with co-morbid factors such as diabetes (25.8 %), peripheral vascular disease (10.4 %), intravenous substance abuse (4.0 %), and HIVpositive infection (1.2 %).
Uključen je ograničen broj bolesnika s istovremeno prisutnim bolestima poput šećerne bolesti (25,80%), periferne vaskularne bolesti (10,4%), ovisnika o intravenskim tvarima (4,0 %) te HIV-pozitivnom infekcijom (1,2%).
The vial should be gently swirled until the medicine is dissolved.
Bočicu treba nježno vrtjeti sve dok se lijek ne otopi.
For intravenous use after reconstitution and dilution.
Za primjenu u venu nakon pripreme i razrjeđivanja.
No loading dose was administered in these studies.
U ovim ispitivanjima nije primijenjena udarna doza.
No dosage adjustment is necessary in patients with renal impairment or in patients undergoing haemodialysis (see section 5.2).
Nije potrebna prilagodba doze u bolesnika s oštećenjem bubrega ili u bolesnika koji su na hemodijalizi (vidjeti dio 5.2).
Common side effects are (may affect up to 1 in 10 people):
Česte nuspojave su (mogu se javiti u do 1 od 10 osoba):
As it is known for tetracycline class antibiotics, tigecycline may also induce permanent dental defects (discolouration and enamel defects) and a delay in ossification processes in foetuses, exposed in utero during the last half of gestation, and in children under eight years of age due to the enrichment in tissues with a high calcium turnover and formation of calcium chelate complexes (see section 4.4).
Kao što je poznato za tetraciklinsku skupinu antibiotika, i tigeciklin može prouzročiti trajna oštećenja zuba (promjena boje i oštećenje cakline), usporiti proces osifikacije kod fetusa koji su bili in utero izloženi tijekom druge polovice trudnoće, kao i u djece mlađe od osam godina uslijed nakupljanja u tkivima s velikom pregradnjom kalcija i stvaranja kompleksa kelata kalcija (vidjeti dio 4.4).
Although hepatic failure may occur in patients treated with tigecycline due to the underlying conditions or concomitant medicinal products, a possible contribution of tigecycline should be considered (see section 4.8).
Iako se zatajenje jetre može javiti u bolesnika liječenih tigeciklinom zbog drugih osnovnih bolesti ili istovremene primjene drugih lijekova, potrebno je razmotriti mogući doprinos tigeciklina (vidjeti dio 4.8).
In clinical studies in complicated skin and soft tissue infections (cSSTI), complicated intra-abdominal infections (cIAI), diabetic foot infections, nosocomial pneumonia and studies in resistant pathogens, a numerically higher mortality rate among tigecycline treated patients has been observed as compared to the comparator treatment.
U kliničkim ispitivanjima s kompliciranim infekcijama kože i mekih tkiva, kompliciranim intraabdominalnim infekcijama, infekcijama dijabetičkog stopala, bolničkom pneumonijom i ispitivanjima rezistentnih patogena, opažena je brojčano veća stopa smrtnosti među bolesnicima koji su primali tigeciklin u odnosu na one koji su primali usporedni lijek.
Tygacil is distributed in a ten vial tray pack.
Tygacil se isporučuje u pakovanju od deset bočica.
These may be symptoms of acute pancreatitis (inflamed pancreas which may result in severe abdominal pain, nausea, and vomiting).
To mogu biti simptomi akutnog pankreatitisa (upale gušterače koja može dovesti do snažne boli u abdomenu, mučnine i povraćanja).
Tigecycline is vulnerable to chromosomally-encoded multi-drug efflux pumps of Proteeae and Pseudomonas aeruginosa.
Tigeciklin je osjetljiv na kromosomski kodirane efluks pumpe za više lijekova u Proteeae i Pseudomonas aeruginosa.
In an open-label, ascending multiple-dose study, 39 children aged 8 to 11 years with cIAI or cSSTI were administered tigecycline (0.75, 1, or 1.25 mg/kg).
U otvorenom ispitivanju s više postupno rastućih doza, 39 djece u dobi od 8 do 11 godina s cIAI or cSSTI dobili su tigeciklin (0,75, 1 ili 1,25 mg/kg).
Tygacil should not be used in children under 8 years of age due to the lack of safety and efficacy data in this age group and because tigecycline may be associated with permanent teeth discolouration (see sections 4.2 and 4.8).
Tygacil se ne smije primjenjivati kod djece mlađe od 8 godina zbog nedostatka podataka o sigurnosti i djelotvornosti u toj dobnoj skupini i zato što tigeciklin može biti povezan s trajnom promjenom boje zuba(vidjeti dijelove 4.2 i 4.8).
Tigecycline should be preferably administered over a 60-minute length of infusion in paediatric patients (see section 4.4).
Tigeciklin treba po mogućnosti primjenjivati u infuziji trajanja 60 minuta u pedijatrijskih bolesnika (vidjeti dio 4.4).
Patients hypersensitive to tetracycline class antibiotics may be hypersensitive to tigecycline.
Bolesnici koji su preosjetljivi na tetraciklinsku skupinu antibiotika mogu biti preosjetljivi i na tigeciklin.
The other ingredients are lactose monohydrate, hydrochloric acid, and sodium hydroxide.
Pomoćne tvari su laktoza hidrat, kloridna kiselina i natrijev hidroksid.
• Jaundice (yellow coloration of the skin), inflammation of the liver
• Žutica (žutilo kože), upala jetre
Concomitant administration of tigecycline and warfarin (25 mg single-dose) to healthy subjects resulted in a decrease in clearance of R-warfarin and S-warfarin by 40 % and 23 %, and an increase in AUC by 68 % and 29 %, respectively.
Istovremena primjena tigeciklina i varfarina (jednokratna doza od 25 mg) kod zdravih ispitanika dovela je do smanjenja klirensa R-varfarina za 40%, a S-varfarina za 23% te porasta AUC-a Rvarfarina za 68% odnosno S-varfarina za 29%.
Bolus intravenous administration of tigecycline has been associated with a histamine response in animal studies.
Bolusna intravenska primjena tigeciklina u ispitivanjima na životinjama povezana je s histaminskomreakcijom.
The single-dose pharmacokinetic disposition of tigecycline was not altered in patients with mild hepatic impairment.
Farmakokinetička raspoloživost tigeciklina nakon jednokratnog doziranja nije bila promijenjena u bolesnika s blagim oštećenjem jetre.
Uncommon side effects are (may affect up to 1 in 100 people):
Manje česte nuspojave su (mogu se javiti u do 1 od 100 osoba):
Tygacil may cause side effects such as dizziness.
Tygacil može uzrokovati nuspojave poput omaglice.
AST and ALT abnormalities in tigecycline-treated patients were reported more frequently in the post therapy period than in those in comparator-treated patients, which occurred more often on therapy.
Poremećaji AST-a i ALT-a u bolesnika koji su primali tigeciklin češće su zabilježeni u razdoblju nakon terapije za razliku od bolesnika koji su primali usporedni lijek kod kojih su bili češći za vrijeme terapije.
In clinical trials in cSSTI, the most common type of infection in tigecycline treated-patients was cellulitis (58.6 %), followed by major abscesses (24.9 %).
U kliničkim ispitivanjima s cSSTI-ovima (engl. complicated skin and soft tissue infections), najčešći oblik infekcije u bolesnika koji su liječeni tigeciklinom bio je celulitis (58,6) , a potom slijede veliki apscesi (24,9).
In all Phase 3 and 4 (cSSTI and cIAI) studies, death occurred in 2.4 % (54/2216) of patients receiving tigecycline and 1.7% (37/2206) of patients receiving active comparators.
U svim ispitivanjima faze 3 i 4 (kompliciranih infekcija kože i mekih tkiva i kompliciranih intraabdominalnih infekcija), smrt je nastupila u 2,4% (54/2216) bolesnika koji su primali tigeciklin i 1,7% (37/2206) bolesnika koji su primali aktivne usporedne lijekove.
5 ml Type 1 clear glass vials fitted with grey butyl rubber stoppers and snap-off aluminium crimp seals.
Bočice od prozirnog stakla tipa 1 od 5 ml, sa sivim čepovima od butil gume i aluminijskim kapicama.
Injection should be made with an infusion solution compatible with tigecycline and any other medicinal product(s) via this common line (see section 6.2)
Infuzijska otopina koja se primjenjuje treba biti kompatibilna s tigeciklinom i drugim lijekovima koji se daju u zajedničkoj liniji (vidjeti dio 6.2)
Co-administration of P-gp inhibitors (e.g., ketoconazole or cyclosporine) or P-gp inducers (e.g., rifampicin) could affect the pharmacokinetics of tigecycline.
Istovremena primjena P-gp inhibitora (npr. ketokonazol ili ciklosporin) ili P-gp induktori (npr. rifampicin) mogu djelovati na farmakokinetiku tigeciklina.
Therefore, it is important to consider this diagnosis in patients who present with diarrhoea during or subsequent to the administration of any antibacterial agent (see section 4.8).
Stoga je ovu dijagnozu nužno uzeti u obzir u bolesnika koji se javljaju zbog proljeva tijekom ili neposredno nakon primjene bilo kojeg antibakterijskog lijeka (vidjeti dio 4.8).
Investigations elevated amylase in serum, increased blood urea nitrogen (BUN)
Pretrage povećana razina amilaze u serumu, povećana razina dušika u krvi (BUN)
Tigecycline may be associated with permanent tooth discolouration in humans if used during tooth development (see section 4.8).
Tigeciklin može biti povezan s trajnom promjenom boje zuba kod ljudi, ukoliko se primjenjuje u razdoblju razvoja zuba (vidjeti dio 4.8).
Once reconstituted and diluted in the bag or other suitable infusion container (e.g. glass bottle), tigecycline should be used immediately.
Nakon pripreme i razrjeđivanja u vrećici ili drugom prikladnom spremniku za infuziju (npr. staklenoj boci), tigeciklin treba odmah primijeniti.
Gastrointestinal disorders nausea, vomiting, diarrhoea abdominal pain, dyspepsia, anorexia acute pancreatitis (see section 4.4)
Poremećaji probavnog sustava mučnina, povraćanje, proljev bol u trbuhu, dispepsija, anoreksija akutni pankreatitis (vidjeti dio 4.4)
For single use only, any unused solution should be discarded.
Isključivo za jednokratnu primjenu; neupotrjebljena otopina mora se baciti.
• Skin rash, which may lead to severe blistering and peeling of the skin (Stevens-Johnson
• Kožni osip, koji može dovesti do izrazitog stvaranja mjehurića i ljuštenja kože (StevensJohnsonov sindrom).
Co-administration of P-gp inhibitors (e.g., ketoconazole or cyclosporine) or P-gp inducers (e.g., rifampicin) could affect the pharmacokinetics of tigecycline (see section 5.2).
Istovremena primjena P-gp inhibitora (npr. ketokonazola ili ciklosporina) ili P-gp induktora (npr. rifampicin) mogu imati utjecaj na farmakokinetički učinak tigeciklina (vidjeti dio 5.2).
This prevents incorporation of amino acid residues into elongating peptide chains.
Na taj se način sprječava ugradnja ostataka aminokiselina u peptidne lance koji se produljuju.
Powder for solution for infusion 10 vials
Prašak za otopinu za infuziju 10 bočica
Tetracycline class antibiotics
Tetraciklinski antibiotici
• Acute pancreatitis (inflamed pancreas which may result in severe abdominal pain, nausea, and vomiting)
• Akutni pankreatitis (upala gušterače koja može rezultirati jakim bolom u trbuhu, mučninom, i povraćanjem)
Consideration should be given to the use of combination antibacterial therapy whenever tigecycline is to be administered to severely ill patients with cIAI secondary to clinically apparent intestinal perforation or patients with incipient sepsis or septic shock (see section 4.8).
Nužan je oprez prilikom primjene kombinacije antibiotika u svim slučajevima u kojima se tigeciklin daje teškim bolesnicima s cIAI-ovima, koje su posljedica klinički verificirane perforacije crijeva ili bolesnicima s početnom sepsom ili septičkim šokom (vidjeti dio 4.8).
Tigecycline in recommended dosage did not affect the rate or extent of absorption, or clearance of digoxin (0.5 mg followed by 0.25 mg daily) when administered in healthy adults.
Tigeciklin primijenjen u zdravih odraslih ispitanika u preporučenoj dozi nije utjecao na brzinu ili opseg apsorpcije ili klirens digoksina (0,5 mg, te potom 0,25 mg dnevno).
• Pruritus (itching), rash
• Pruritus (svrbež), osip
This in vitro information is consistent with the lack of effect of tigecycline on digoxin clearance noted in the in vivo drug interaction study described above (see section 4.5).
Ta in vitro informacija koja je konzistentna sa smanjenjem učinka tigeciklina na klirens digoksina, zabilježenog u in vivo studiji interakcije opisana je u tekstu gore (vidjeti dio 4.5).
Tygacil should not be used in children aged under 8 years because of teeth discolouration (see sections 4.4 and 5.1).
Tygacil se ne smije primjenjivati u djece ispod 8 godina starosti zbog promjene boje zubi (vidjeti dijelove 4.4 i 5.1).
If a focus of infection other than cSSTI or cIAI is identified after initiation of tigecycline therapy consideration should be given to instituting alternative antibacterial therapy that has been demonstrated to be efficacious in the treatment of the specific type of infection(s) present.
Ako se ustanovi žarište infekcije različito od komplicirane infekcije kože i mekih tkiva ili komplicirane intraabdominalne infekcije nakon uvođenja liječenja tigeciklinom, potrebno je razmotriti uvođenje alternativnog antibakterijskog liječenja koje se pokazalo djelotvorno u liječenju specifičnog tipa prisutne infekcije (ili više njih).
Adolescents aged 12 to <18 years: 50 mg of tigecycline every 12 hours for 5 to 14 days.
Adolescenti u dobi od 12 do <18 godina: 50 mg tigeciklina svakih 12 sati tijekom 5 do 14 dana.
Nervous system disorders dizziness
Poremećaji živčanog sustava omaglica
Skin and subcutaneous tissue disorders pruritus, rash severe skin reactions, including Stevens-Johnson Syndrome
Teške kožne reakcije, uključujući Stevens-Johnson sindrom
Tigecycline should be administered intravenously through a dedicated line or through a Y-site.
Tigeciklin se mora primjenjivati intravenski kroz zasebnu liniju ili Y-liniju.
The target AUC0-12h in adults after the recommended dose of 100 mg loading and 50 mg every 12 hours, was approximately 2500 ng•h/mL.
Ciljni AUC0-12h u odraslih nakon preporučene udarne doze od 100 mg te potom 50 mg svakih 12 sati iznosio je približno 2500 ng•h/ml.
• Vein irritations from the injection, including pain, inflammation, swelling and clotting
• Nadraženost vene na mjestu injekcije, uključujući bol, upalu, oteklinu i ugruške
Renal clearance is approximately 13 % of total clearance.
Bubrežni klirens iznosi otprilike 13% ukupnog klirensa.
(Cyprus Branch), Τηλ: +357 22 817690
Pfizer ΕΛΛΑΣ Α.Ε. (Cyprus Branch), Τηλ: +357 22 817690
The safety of tigecycline was also investigated in an open-label, ascending multi-dose PK study in 58 children aged 8 to 11 years with cSSTI (n=15), cIAI (n=24) or community-acquired pneumonia (n=19).
Sigurnost tigeciklina također je ispitivana u otvorenom farmakokinetičkom ispitivanju s više postupno rastućih doza u 58 djece u dobi od 8 do 11 godina s kompliciranim infekcijama kože i mekih tkiva (n=15), kompliciranim intraabdominalnim infekcijama (n=24) ili upalom pluća zadobivenom u socijalnim kontaktima (n=19).
Justification for not including Braille accepted.
16. PODACI NA BRAILLEOVOM PISMU Prihvaćeno obrazloženje za ne navođenje Braillea
Cross-resistance between tigecycline and minocycline-resistant isolates among the Enterobacteriaceae due to multi-drug resistance (MDR) efflux pumps has been shown.
Pokazalo se da kod Enterobacteriaceae postoji križna rezistencija u izolata rezistentnih na tigeciklin i minociklin zbog efluks-pumpi rezistencije na više lijekova (MDR; od engl. multi-drug resistance).